Pharmakon Advisors, LP
Overview
Pharmakon Advisors, LP is an investment management firm specializing in providing strategic financing solutions to the life sciences industry. Since its founding in 2009, Pharmakon has raised approximately $5.1 billion across five private funds and a publicly traded UK trust: BioPharma Credit PLC (ticker: BPCR.L), which was listed on the London Stock Exchange in March 2017. The firm has committed over $10 billion across 62 transactions supporting companies in the life sciences, including biotechnology, pharmaceuticals, medical technology, and diagnostics. Pharmakon's investment approach is comprehensive and flexible, specializing in providing non-dilutive debt capital to a broad spectrum of life sciences companies—from emerging growth innovators to established commercial-stage companies. The firm's team comprises seasoned professionals with deep expertise spanning biotechnology, pharmaceuticals, medical technology, and finance. This collective experience enables Pharmakon to deliver customized financing solutions for companies while generating competitive risk-adjusted returns for investors. Notable transactions include a $250 million convertible bond issuance for Amicus, Inc. in December 2016, a $150 million royalty loan to subsidiaries of Halozyme, Inc. in January 2016, and a $175 million senior secured loan to Merrimack, Inc. in December 2015. These investments highlight Pharmakon's commitment to supporting innovative companies in the life sciences sector through strategic financing solutions.
Investment Focus
- Non-dilutive debt financing
- Established life sciences companies
- Commercial-stage companies
- Emerging growth innovators
Portfolio Companies
Reach Pharmakon Advisors, LP directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Pharmakon Advisors, LP
What sectors does Pharmakon Advisors, LP invest in?
Pharmakon Advisors, LP invests in Pharmaceuticals, Diagnostics, Biotechnology and Medical Technology, and is based in New York, United States. Pharmakon Advisors, LP is listed as a private investment firm in the ConnectSafely investor database.
What stage does Pharmakon Advisors, LP invest at?
Pharmakon Advisors, LP backs companies at Growth, Late Stage and Pre-IPO, writing cheques of 50M - 500M.
Which regions does Pharmakon Advisors, LP invest in?
Pharmakon Advisors, LP invests across United States, United Kingdom, Germany, France, Italy and Denmark.
Who are the partners at Pharmakon Advisors, LP?
Team members listed for Pharmakon Advisors, LP include Simon Gruber (Vice President) and Scott Levitt (Vice President, Healthcare Research and Investments).
What companies has Pharmakon Advisors, LP invested in?
Pharmakon Advisors, LP's portfolio includes iRhythm Technologies, Evolus, DepoMed, Amicus Therapeutics, Halozyme Therapeutics and Merrimack Pharmaceuticals.
How do I contact Pharmakon Advisors, LP?
Pharmakon Advisors, LP's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
